TrialPath

Find a study

Studies of GLP-1, incretin, and related peptide medications for weight and metabolic health.

Match me to a study

3 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

  • Kidney disease

    The Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients

    Testing a 12-week diabetes medicine combination in kidney transplant patients with kidney disease

    📍 Toronto General Hospital · Toronto, Ontario · Get directions →

    The study aims to determine the short-term efficacy, mechanisms and safety of 12 weeks of dapagliflozin and semaglutide combination therapy in 20 KTR, with and without T2D.

    ✓ Study care freePhase 2Ages 18+Learn more →
  • Multiple sclerosis (MS)

    Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis

    Testing a medicine to reduce brain and eye tissue loss in people with multiple sclerosis

    📍 Johns Hopkins University · Baltimore, MD · +1 more US site · Get directions →

    The goal of this clinical trial is to evaluate if the study drug will reduce brain and retinal atrophy by reducing inflammation and subsequently slowing neurodegeneration in people with Multiple Sclerosis. The main outcome for the trial is change in normalized brain parenchymal volume (nBPV), measured by magnetic resonance imaging (MRI).

    ✓ Study care freePhase 2Ages 18–60Learn more →
  • Obesity / overweightKidney disease

    Glucagon-Like Peptide-1 Receptor Agonist in ADPKD

    Testing a 1-year weight-loss medicine to slow kidney cyst growth in adults with ADPKD

    📍 University of Colorado - Anschutz Medical Campus · Aurora, CO · Get directions →

    The proposed clinical trial aims to assess if a year of treatment with a glucagon-like peptide 1 receptor agonist, a medication approved for weight management that also improves the body's response to glucose and insulin, can slow kidney growth in adults with autosomal dominant polycystic kidney disease who are overweight or obese. The study will also evaluate changes in abdominal fat and kidney metabolism using cutting-edge images techniques.

    ✓ Study care freePhase 2Ages 18–65Learn more →